Neurologic Imaging

What Is the Best Initial Imaging for a Parotid Region Mass? An ACR-Guided Workflow

·
What Is the Best Initial Imaging for a Parotid Region Mass? An ACR-Guided Workflow

A 58-year-old patient presents to your clinic with a firm, painless, slowly enlarging lump just below their left earlobe, which they first noticed two months ago. On exam, the mass is mobile and located within the tail of the parotid gland. You suspect a salivary gland neoplasm, but the differential is broad, ranging from benign tumors to malignancy. Your immediate question is what imaging study to order first to characterize the mass and guide the next steps. This article details the American College of Radiology (ACR) recommended workflow for this exact scenario. For the initial imaging of a parotid region mass, a neck ultrasound is rated Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to adult and pediatric patients presenting with one or more discrete, palpable masses in the parotid region, which includes the preauricular area and the retromandibular space. The recommendation is for the initial diagnostic imaging workup, not for surveillance of a known lesion or post-treatment follow-up. The patient may be asymptomatic or have associated symptoms like mild tenderness, but the primary finding is a focal mass, not diffuse, exquisitely painful glandular swelling suggestive of acute bacterial sialadenitis.

It is critical to distinguish this presentation from similar but distinct clinical problems that follow different diagnostic pathways:

  • Pulsatile Neck Mass: If the mass is clearly pulsatile on exam or auscultation reveals a bruit, the workup shifts to a vascular etiology. This follows the ACR variant for Pulsatile neck mass(es).
  • Mass Clearly Outside the Parotid: If the mass is located in the anterior or posterior cervical triangles, supraclavicular fossa, or midline, and is not contiguous with the parotid gland, it falls under the Nonpulsatile neck mass(es) variant.
  • Thyroid Nodule: A mass in the low anterior neck that moves with swallowing is presumed to be of thyroid origin and has its own dedicated ACR Appropriateness Criteria.

Correctly identifying your patient’s scenario ensures the most efficient and appropriate diagnostic cascade.

What Diagnoses Are You Working Up in This Scenario?

When evaluating a parotid mass, the primary goal of imaging is to confirm the mass is intraparotid, characterize its features (solid vs. cystic), assess for signs of malignancy, and evaluate regional lymph nodes. The differential diagnosis is broad, but imaging helps narrow the possibilities.

The most common parotid neoplasm by a wide margin is the pleomorphic adenoma, also known as a benign mixed tumor. These account for the majority of all parotid tumors and typically present as the classic slow-growing, painless, firm, mobile mass. While benign, they have the potential for malignant transformation if left untreated for many years.

Another common benign entity is the Warthin tumor (papillary cystadenoma lymphomatosum). It is strongly associated with smoking, typically affects older men, and is notable for being bilateral or multifocal in a significant minority of cases. On imaging, they often have prominent cystic components.

The most common primary malignancy is mucoepidermoid carcinoma. These can be low-grade, mimicking a benign tumor’s slow growth, or high-grade, presenting with rapid enlargement, pain, skin fixation, or facial nerve (CN VII) palsy. Imaging features suggesting malignancy include ill-defined margins, invasion into adjacent tissues, and pathologic cervical lymphadenopathy.

Other considerations include non-neoplastic causes like a focal presentation of chronic sialadenitis or an intraparotid lymph node, which could be reactive from a local infection or neoplastic from lymphoma or metastasis (most commonly from a cutaneous squamous cell carcinoma of the head and neck).

Why Is Ultrasound the Recommended First Study for a Parotid Mass?

For the initial evaluation of a palpable parotid region mass, three modalities are rated Usually Appropriate by the ACR: US neck, MRI neck with and without IV contrast, and CT neck with IV contrast. However, ultrasound is the preferred first-line study due to its combination of high diagnostic yield, safety, and practicality.

The primary strength of ultrasound is its excellent spatial resolution, allowing for detailed characterization of the mass. It can reliably distinguish solid from cystic lesions, define margins, assess internal architecture, and measure vascularity with color Doppler. This information is crucial for narrowing the differential. Furthermore, ultrasound is the ideal modality for guiding fine-needle aspiration (FNA), which is often the definitive next step for obtaining a cytological diagnosis. This can frequently be performed in the same session as the diagnostic ultrasound, streamlining the patient’s workup.

Most importantly, ultrasound is non-invasive and safe. It involves no ionizing radiation (adult radiation relative level: O, 0 mSv) and does not require intravenous contrast, avoiding potential allergic reactions or nephrotoxicity. Its widespread availability and lower cost compared to cross-sectional imaging make it the most efficient initial test.

While effective, other modalities are typically reserved for specific situations:

  • CT neck with IV contrast: This is also rated Usually Appropriate but exposes the patient to ionizing radiation (adult radiation relative level: ☢☢☢, 1-10 mSv). It is superior for evaluating for bony erosion and detecting sialoliths (salivary stones). It is often used for surgical planning, especially for large tumors or when malignancy is highly suspected.
  • MRI neck without and with IV contrast: Also Usually Appropriate, MRI offers superior soft-tissue contrast resolution, making it the best modality for assessing perineural spread of a malignancy along the facial nerve and for delineating the relationship of a mass to the deep lobe of the parotid gland. It is often the preferred modality for problem-solving after an indeterminate ultrasound or for preoperative planning.
  • FDG-PET/CT: This is rated Usually not appropriate for initial characterization. Its role is limited to staging of known high-grade malignancies or evaluating for recurrence, not for the initial workup of an undifferentiated mass.

What Is the Downstream Workflow After a Parotid Ultrasound?

The results of the initial neck ultrasound will dictate the subsequent management plan, which almost always involves a referral to an Otolaryngologist (ENT surgeon).

  • If the US shows a well-defined, homogeneous mass with features classic for a benign neoplasm (e.g., pleomorphic adenoma): The next step is typically an ENT consultation. The surgeon may proceed with US-guided FNA to confirm the diagnosis preoperatively. For smaller, classic-appearing tumors, some surgeons may opt for surgical excision without prior FNA.
  • If the US shows features suspicious for malignancy (e.g., spiculated margins, local invasion, perineural extension, or associated pathologic cervical lymph nodes): An urgent ENT referral is warranted. US-guided FNA of the primary mass and any suspicious lymph nodes is the critical next step to establish a tissue diagnosis and guide further treatment. Preoperative cross-sectional imaging with CT or MRI will almost certainly be required for staging and surgical planning.
  • If the US is indeterminate or shows a large tumor involving the deep lobe of the parotid: MRI neck with and without IV contrast is the preferred next imaging step. MRI provides superior detail of the tumor’s extent, its relationship to the facial nerve, and potential intracranial extension, which is vital information for the surgeon.
  • If the US is negative or shows only diffuse glandular changes without a discrete mass: The clinical picture should be reconsidered. If symptoms suggest an inflammatory process like Sjogren’s syndrome or chronic sialadenitis, further rheumatologic or medical workup may be indicated.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for a parotid mass requires careful attention to detail to avoid common missteps.

  • Pitfall 1: Assuming a slow-growing mass is benign. While often true, low-grade malignancies like mucoepidermoid carcinoma can grow slowly for years. All discrete, solid parotid masses warrant a full workup.
  • Pitfall 2: Not evaluating the facial nerve. A key part of the physical exam is assessing the function of all branches of the facial nerve (CN VII). Any weakness or paralysis is a significant red flag for malignancy and warrants an expedited workup and referral.
  • Pitfall 3: Ordering the wrong cross-sectional study. If cross-sectional imaging is needed after ultrasound, MRI is generally preferred for soft-tissue detail and facial nerve evaluation, while CT is better for assessing bony invasion. Ordering the non-optimal study may lead to redundant imaging.
  • Pitfall 4: Forgetting the skin. Always perform a thorough skin exam of the scalp, face, and ear. Metastases from cutaneous squamous cell carcinoma are a common cause of malignant intraparotid masses.

If any red flags for malignancy are present—including facial nerve palsy, rapid growth, skin ulceration, or fixation of the mass to surrounding tissue—escalate care with an urgent referral to an ENT specialist.

Related ACR Topics and Tools

This article focuses on one specific clinical scenario. For a comprehensive overview of all variants or to explore the tools used to develop this guidance, please refer to the following resources. For breadth across all scenarios in Neck Mass/Adenopathy, see our parent guide: Neck Mass/Adenopathy: ACR Appropriateness Decoded.

Frequently Asked Questions

Is a CT or MRI ever the right first-line study for a parotid mass?

While both CT and MRI are rated ‘Usually Appropriate’ by the ACR, ultrasound is the preferred initial study due to its lack of radiation, lower cost, and ability to guide biopsy in the same session. A clinician might choose to start with CT or MRI in specific circumstances, such as a patient with a very large, fixed mass where deep extension and bony invasion are highly suspected from the outset, or in a patient for whom ultrasound is technically limited.

What if the patient has symptoms of facial nerve weakness with the parotid mass?

Facial nerve palsy in the setting of a parotid mass is a significant red flag for malignancy. While ultrasound is still a reasonable first step to confirm and characterize the mass for biopsy, MRI with and without contrast is the superior study for evaluating perineural spread along the facial nerve. An urgent referral to an ENT surgeon is mandatory in this situation.

Does the imaging recommendation change if there are multiple masses in the parotid gland?

Not for the initial study. Ultrasound remains the best first step. The presence of multiple masses narrows the differential diagnosis. Warthin tumors and intraparotid lymph nodes (due to benign or malignant causes) are well-known for being multifocal or bilateral. Ultrasound can characterize each of the lesions to guide further management.

Should I order a fine-needle aspiration (FNA) at the same time as the ultrasound?

It is often efficient to coordinate a diagnostic ultrasound with a potential US-guided FNA. However, the decision to perform an FNA is typically made in consultation with the treating specialist (ENT). A common workflow is for the primary physician to order the diagnostic ultrasound, and upon its findings, refer the patient to ENT, who will then arrange for the FNA if indicated.

What is the role of sialography in working up a parotid mass?

Conventional fluoroscopic sialography and CT/MR sialography are generally not used for the initial evaluation of a discrete parotid mass. Their primary role is in evaluating ductal abnormalities in the setting of recurrent inflammation, obstruction (sialolithiasis), or strictures, rather than characterizing a parenchymal tumor. For this scenario, MRI with parotid sialography is rated ‘May be appropriate’, but it is not a first-line test.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026